| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | For the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy. |
| Assessment Process | |
| Rapid review commissioned | 03/05/2017 |
| Rapid review completed | 30/05/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations May 2018.